Harmony Biosciences Holdings, Inc. (HRMY)
NASDAQ: HRMY · IEX Real-Time Price · USD
33.52
+1.50 (4.68%)
At close: Mar 27, 2024, 4:00 PM
34.64
+1.12 (3.34%)
After-hours: Mar 27, 2024, 6:14 PM EDT
HRMY Stock Forecast
Stock Price Forecast
The 9 analysts with 12-month price forecasts for HRMY stock have an average target of 43.78, with a low estimate of 27 and a high estimate of 69. The average target predicts an increase of 30.61% from the current stock price of 33.52.
Analyst Consensus: Buy
* Price targets were last updated on Feb 27, 2024.
Analyst Ratings
The average analyst rating for HRMY stock from 9 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
Rating | Oct '23 | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 |
---|---|---|---|---|---|---|
Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
Buy | 4 | 4 | 4 | 4 | 4 | 4 |
Hold | 1 | 1 | 1 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 1 | 1 | 1 |
Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
Total | 9 | 9 | 9 | 9 | 9 | 9 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Mizuho | Mizuho | Strong Buy Maintains $42 → $40 | Strong Buy | Maintains | $42 → $40 | +19.33% | Feb 27, 2024 |
Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $49 | Buy | Reiterates | $49 | +46.18% | Feb 23, 2024 |
Needham | Needham | Strong Buy Maintains $53 → $50 | Strong Buy | Maintains | $53 → $50 | +49.16% | Feb 23, 2024 |
Needham | Needham | Strong Buy Reiterates $53 | Strong Buy | Reiterates | $53 | +58.11% | Feb 22, 2024 |
Mizuho | Mizuho | Strong Buy Maintains $33 → $42 | Strong Buy | Maintains | $33 → $42 | +25.30% | Feb 16, 2024 |
Financial Forecast
Revenue This Year
726.03M
from 582.02M
Increased by 24.74%
Revenue Next Year
857.44M
from 726.03M
Increased by 18.10%
EPS This Year
2.97
from 2.13
Increased by 39.28%
EPS Next Year
4.10
from 2.97
Increased by 38.11%
Revenue Forecast
Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | 755.2M | 934.3M | 1.2B | 1.9B | 2.1B |
Avg | 726.0M | 857.4M | 1.0B | 1.2B | 1.3B |
Low | 686.4M | 773.0M | 829.8M | 791.3M | 551.4M |
Revenue Growth
Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | 29.7% | 28.7% | 36.8% | 86.5% | 72.6% |
Avg | 24.7% | 18.1% | 16.9% | 20.5% | 6.4% |
Low | 17.9% | 6.5% | -3.2% | -21.0% | -54.3% |
EPS Forecast
EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | 3.62 | 5.17 | 6.84 | 9.44 | 10.86 |
Avg | 2.97 | 4.10 | 5.19 | 7.68 | 7.28 |
Low | 2.40 | 3.28 | 4.14 | 5.94 | 3.86 |
EPS Growth
EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | 70.1% | 74.1% | 66.8% | 81.8% | 41.5% |
Avg | 39.3% | 38.1% | 26.7% | 47.8% | -5.1% |
Low | 12.7% | 10.7% | 0.9% | 14.4% | -49.7% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.